Evidence map›Paper›PMID 25577314›Full record

ArticleJournal of the neurological sciences2015

Collagen Q--a potential target for autoantibodies in myasthenia gravis.

Marta Zoltowska Katarzyna, Katsiaryna Belaya, Maria Leite, Waters Patrick, Angela Vincent, David Beeson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the neurological sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  6. Review
  7. Fc-Receptor Targeted Therapies for the Treatment ofInternational journal of molecular sciences · 2021
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Controversies in Ocular Myasthenia Gravis.Frontiers in neurology · 2020
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Marta Zoltowska KatarzynaNuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Weatherall Institute of Molecular Medicine, Neurosciences Group, OX3 9DS, Oxford, UK.
Katsiaryna BelayaNuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Weatherall Institute of Molecular Medicine, Neurosciences Group, OX3 9DS, Oxford, UK.
Maria LeiteNuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Weatherall Institute of Molecular Medicine, Neurosciences Group, OX3 9DS, Oxford, UK.
Waters PatrickNuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Weatherall Institute of Molecular Medicine, Neurosciences Group, OX3 9DS, Oxford, UK.
Angela VincentNuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Weatherall Institute of Molecular Medicine, Neurosciences Group, OX3 9DS, Oxford, UK.
David BeesonNuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Weatherall Institute of Molecular Medicine, Neurosciences Group, OX3 9DS, Oxford, UK. Electronic address: david.beeson@ndcn.ox.ac.uk.
John Radcliffe Hospital · GB

Funding

Medical Research Council MR/M006824/1Wellcome Trust 084655
6 · The paper itself

Abstract

Myasthenia gravis (MG) is an autoimmune disorder caused by autoantibodies targeting proteins expressed at the neuromuscular junction (NMJ). In most cases the targets are acetylcholine receptor (AChR), muscle-specific tyrosine kinase (MuSK), or occasionally low-density lipoprotein receptor-related protein 4 (LRP4), but there is still a group of patients, often called seronegative MG (SNMG), with unknown antibody targets. One potential target is collagen Q (COLQ), which is restricted to the NMJ and is crucial for anchoring the NMJ-specific form of acetylcholinesterase (AChE). 415 serum samples with a clinical diagnosis of MG and 43 control samples were screened for the presence of COLQ autoantibodies using a cell-based assay (CBA) with HEK293 cells overexpressing COLQ at the cell surface. COLQ antibodies were detected in 12/415 MG sera and in one/43 control samples. Five of the COLQ-Ab+individuals were also positive for AChR-Abs and 2 for MuSK-Abs. Although the COLQ antibodies were only present at low frequency, and did not differ significantly from the small control cohort, further studies could address whether they modify the clinical presentation or the benefits of anti-cholinesterase therapy.

Indexed as

AcetylcholinesteraseAdolescentAdultAgedAutoantibodiesBiological AssayChildCollagenFemaleHEK293 CellsHumansMiddle AgedMuscle ProteinsMyasthenia GravisYoung AdultAcetylcholinesteraseAutoantibodiesCollagenCOLQ protein, humanMuscle ProteinsAutoantibodiesCell-based assay (CBA)Collagen Q (COLQ)Myasthenia gravis (MG)NeuroimmunologyNeuromuscular junction (NMJ)

Identifiers

PMID25577314
PMCPMC6044427
OpenAlexW2095672233

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.